Titre : Virus spumeux simien

Virus spumeux simien : Questions médicales fréquentes

Termes MeSH sélectionnés :

C-Reactive Protein
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Virus spumeux simien : Questions médicales les plus fréquentes", "headline": "Virus spumeux simien : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Virus spumeux simien : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-02-15", "dateModified": "2025-05-10", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Virus spumeux simien" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Spumavirus", "url": "https://questionsmedicales.fr/mesh/D016092", "about": { "@type": "MedicalCondition", "name": "Spumavirus", "code": { "@type": "MedicalCode", "code": "D016092", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "B04.820.650.850" } } }, "about": { "@type": "MedicalCondition", "name": "Virus spumeux simien", "alternateName": "Simian foamy virus", "code": { "@type": "MedicalCode", "code": "D053150", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Antoine Gessain", "url": "https://questionsmedicales.fr/author/Antoine%20Gessain", "affiliation": { "@type": "Organization", "name": "Unité d'Epidémiologie et Physiopathologie des Virus Oncogènes, Institut Pasteur, UMR3569 CNRS, Paris, France." } }, { "@type": "Person", "name": "Florence Buseyne", "url": "https://questionsmedicales.fr/author/Florence%20Buseyne", "affiliation": { "@type": "Organization", "name": "Institut Pasteur, Unité d'Epidémiologie et Physiopathologie des Virus Oncogènes, Institut Pasteur, 28 rue du Dr Roux, 75015, Paris, France; UMR CNRS 3569, Institut Pasteur, 28 rue du Dr Roux, 75015, Paris, France. Electronic address: florence.buseyne@pasteur.fr." } }, { "@type": "Person", "name": "Juan Tan", "url": "https://questionsmedicales.fr/author/Juan%20Tan", "affiliation": { "@type": "Organization", "name": "Key Laboratory of Molecular Microbiology and Technology, Ministry of Education, College of Life Sciences, Nankai University, Tianjin, 300071, China." } }, { "@type": "Person", "name": "Martin Löchelt", "url": "https://questionsmedicales.fr/author/Martin%20L%C3%B6chelt", "affiliation": { "@type": "Organization", "name": "German Cancer Research Center DKFZ, Program Infection, Inflammation and Cancer, Division of Viral Transformation Mechanisms, 69120 Heidelberg, Germany." } }, { "@type": "Person", "name": "Wentao Qiao", "url": "https://questionsmedicales.fr/author/Wentao%20Qiao", "affiliation": { "@type": "Organization", "name": "Key Laboratory of Molecular Microbiology and Technology, Ministry of Education, College of Life Sciences, Nankai University, Tianjin, 300071, China. wentaoqiao@nankai.edu.cn." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "C-Reactive Protein as a Prognostic Biomarker for Gynecologic Cancers: A Meta-Analysis.", "datePublished": "2022-10-11", "url": "https://questionsmedicales.fr/article/36268143", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1155/2022/6833078" } }, { "@type": "ScholarlyArticle", "name": "Regulation of Conformational Changes in C-reactive Protein Alters its Bioactivity.", "datePublished": "2022-08-23", "url": "https://questionsmedicales.fr/article/35997934", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s12013-022-01089-x" } }, { "@type": "ScholarlyArticle", "name": "A rapid fluorescent aptasensor for point-of-care detection of C-reactive protein.", "datePublished": "2022-06-04", "url": "https://questionsmedicales.fr/article/35714415", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.talanta.2022.123661" } }, { "@type": "ScholarlyArticle", "name": "C-reactive protein and 10-year cardiovascular risk in rheumatoid arthritis.", "datePublished": "2022-07-09", "url": "https://questionsmedicales.fr/article/35821191", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.ejim.2022.07.001" } }, { "@type": "ScholarlyArticle", "name": "C-reactive protein to lymphocyte count ratio is a promising novel marker in hepatitis C infection: the clear hep-c study.", "datePublished": "2022-06-24", "url": "https://questionsmedicales.fr/article/35766701", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1590/1806-9282.20220236" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Virus", "item": "https://questionsmedicales.fr/mesh/D014780" }, { "@type": "ListItem", "position": 3, "name": "Virus à ARN", "item": "https://questionsmedicales.fr/mesh/D012328" }, { "@type": "ListItem", "position": 4, "name": "Retroviridae", "item": "https://questionsmedicales.fr/mesh/D012190" }, { "@type": "ListItem", "position": 5, "name": "Spumavirus", "item": "https://questionsmedicales.fr/mesh/D016092" }, { "@type": "ListItem", "position": 6, "name": "Virus spumeux simien", "item": "https://questionsmedicales.fr/mesh/D053150" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Virus spumeux simien - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Virus spumeux simien", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-13", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Virus spumeux simien", "description": "Comment diagnostiquer une infection par le SFV ?\nQuels tests sont utilisés pour le SFV ?\nLe SFV peut-il être détecté chez l'homme ?\nQuels échantillons sont nécessaires pour le diagnostic ?\nLe SFV est-il transmissible entre espèces ?", "url": "https://questionsmedicales.fr/mesh/D053150?mesh_terms=C-Reactive+Protein&page=3#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Virus spumeux simien", "description": "Quels sont les symptômes d'une infection par le SFV ?\nLe SFV cause-t-il des maladies chez les primates ?\nY a-t-il des symptômes chez les humains infectés ?\nLe SFV peut-il provoquer des symptômes neurologiques ?\nLe SFV est-il associé à d'autres infections ?", "url": "https://questionsmedicales.fr/mesh/D053150?mesh_terms=C-Reactive+Protein&page=3#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Virus spumeux simien", "description": "Comment prévenir l'infection par le SFV ?\nLes vaccins existent-ils contre le SFV ?\nLe SFV se propage-t-il par contact humain ?\nQuelles précautions prendre avec les primates ?\nLes tests de dépistage sont-ils recommandés ?", "url": "https://questionsmedicales.fr/mesh/D053150?mesh_terms=C-Reactive+Protein&page=3#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Virus spumeux simien", "description": "Quel traitement existe pour le SFV ?\nLe SFV nécessite-t-il un traitement préventif ?\nLes antiviraux sont-ils efficaces contre le SFV ?\nLe SFV nécessite-t-il une surveillance médicale ?\nY a-t-il des traitements expérimentaux pour le SFV ?", "url": "https://questionsmedicales.fr/mesh/D053150?mesh_terms=C-Reactive+Protein&page=3#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Virus spumeux simien", "description": "Quelles complications peuvent survenir avec le SFV ?\nLe SFV est-il lié à d'autres maladies ?\nLe SFV peut-il affecter le système immunitaire ?\nY a-t-il des risques de cancer liés au SFV ?\nLe SFV peut-il causer des infections opportunistes ?", "url": "https://questionsmedicales.fr/mesh/D053150?mesh_terms=C-Reactive+Protein&page=3#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Virus spumeux simien", "description": "Qui est à risque d'infection par le SFV ?\nLes travailleurs de laboratoire sont-ils à risque ?\nLes voyageurs dans des zones endommagées sont-ils à risque ?\nLes personnes ayant des animaux de compagnie sont-elles à risque ?\nLes personnes immunodéprimées sont-elles plus à risque ?", "url": "https://questionsmedicales.fr/mesh/D053150?mesh_terms=C-Reactive+Protein&page=3#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une infection par le SFV ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Le diagnostic se fait par des tests sérologiques ou PCR pour détecter le virus." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour le SFV ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Les tests ELISA et PCR sont couramment utilisés pour identifier le SFV." } }, { "@type": "Question", "name": "Le SFV peut-il être détecté chez l'homme ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des anticorps contre le SFV ont été trouvés chez des humains, mais sans symptômes." } }, { "@type": "Question", "name": "Quels échantillons sont nécessaires pour le diagnostic ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Des échantillons de sang ou de tissus peuvent être nécessaires pour le diagnostic." } }, { "@type": "Question", "name": "Le SFV est-il transmissible entre espèces ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Le SFV est principalement transmis entre primates, mais des cas chez l'homme sont possibles." } }, { "@type": "Question", "name": "Quels sont les symptômes d'une infection par le SFV ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Le SFV est généralement asymptomatique chez les hôtes, y compris les primates et les humains." } }, { "@type": "Question", "name": "Le SFV cause-t-il des maladies chez les primates ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Non, le SFV ne cause pas de maladies cliniques chez les primates infectés." } }, { "@type": "Question", "name": "Y a-t-il des symptômes chez les humains infectés ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Les humains infectés par le SFV ne présentent généralement aucun symptôme clinique." } }, { "@type": "Question", "name": "Le SFV peut-il provoquer des symptômes neurologiques ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Aucune preuve ne montre que le SFV provoque des symptômes neurologiques chez l'homme." } }, { "@type": "Question", "name": "Le SFV est-il associé à d'autres infections ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Le SFV peut coexister avec d'autres infections virales, mais sans lien direct." } }, { "@type": "Question", "name": "Comment prévenir l'infection par le SFV ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Éviter le contact avec des primates infectés est la meilleure prévention contre le SFV." } }, { "@type": "Question", "name": "Les vaccins existent-ils contre le SFV ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Il n'existe pas de vaccin spécifique contre le SFV, car il est généralement inoffensif." } }, { "@type": "Question", "name": "Le SFV se propage-t-il par contact humain ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "La transmission interhumaine du SFV est rare et non documentée dans la littérature." } }, { "@type": "Question", "name": "Quelles précautions prendre avec les primates ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Évitez de manipuler des primates sauvages et respectez les protocoles de sécurité." } }, { "@type": "Question", "name": "Les tests de dépistage sont-ils recommandés ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Les tests de dépistage ne sont pas recommandés pour la population générale, car asymptomatique." } }, { "@type": "Question", "name": "Quel traitement existe pour le SFV ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Il n'existe pas de traitement spécifique pour le SFV, car il est généralement asymptomatique." } }, { "@type": "Question", "name": "Le SFV nécessite-t-il un traitement préventif ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Non, aucun traitement préventif n'est nécessaire en raison de l'absence de symptômes." } }, { "@type": "Question", "name": "Les antiviraux sont-ils efficaces contre le SFV ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Les antiviraux ne sont pas utilisés contre le SFV, car il ne cause pas de maladie." } }, { "@type": "Question", "name": "Le SFV nécessite-t-il une surveillance médicale ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Une surveillance n'est pas nécessaire, car le SFV est généralement inoffensif." } }, { "@type": "Question", "name": "Y a-t-il des traitements expérimentaux pour le SFV ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Actuellement, il n'y a pas de traitements expérimentaux spécifiques pour le SFV." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec le SFV ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Le SFV ne cause pas de complications cliniques connues chez les hôtes infectés." } }, { "@type": "Question", "name": "Le SFV est-il lié à d'autres maladies ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Aucune association directe entre le SFV et d'autres maladies n'a été établie." } }, { "@type": "Question", "name": "Le SFV peut-il affecter le système immunitaire ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Il n'y a pas de preuve que le SFV affecte le système immunitaire des hôtes." } }, { "@type": "Question", "name": "Y a-t-il des risques de cancer liés au SFV ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Aucune preuve ne lie le SFV à un risque accru de cancer chez les hôtes infectés." } }, { "@type": "Question", "name": "Le SFV peut-il causer des infections opportunistes ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Le SFV n'est pas connu pour causer des infections opportunistes chez les hôtes." } }, { "@type": "Question", "name": "Qui est à risque d'infection par le SFV ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les personnes en contact étroit avec des primates sont à risque d'infection par le SFV." } }, { "@type": "Question", "name": "Les travailleurs de laboratoire sont-ils à risque ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les chercheurs manipulant des primates ou des échantillons de SFV sont à risque." } }, { "@type": "Question", "name": "Les voyageurs dans des zones endommagées sont-ils à risque ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les voyageurs dans des zones avec des primates sauvages peuvent être à risque." } }, { "@type": "Question", "name": "Les personnes ayant des animaux de compagnie sont-elles à risque ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Le risque est faible, mais les personnes avec des primates comme animaux de compagnie sont à risque." } }, { "@type": "Question", "name": "Les personnes immunodéprimées sont-elles plus à risque ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Il n'y a pas de preuve que les personnes immunodéprimées soient plus à risque d'infection par le SFV." } } ] } ] }

Sources (10000 au total)

C-Reactive Protein as a Prognostic Biomarker for Gynecologic Cancers: A Meta-Analysis.

The prognostic role of CRP (C-reactive protein) in gynecological tumors has been previously reported in individual studies, but whether CRP can be used as a separate potential prognostic factor has no... A systematic search was carried out to find the literature evaluating the predictive role of CRP in the prognosis of gynecological cancer patients. For the purpose of determining the relationship betw... A total of 19 studies, including 4062 patients, were analyzed retrospectively. The FIGO stage was related to the CRP level (OR = 0.43, 95% CI: 0.19-1.00). Age, lymph node metastasis, and histological ... CRP may be utilized as a prognostic indicator for a variety of gynecologic malignancies, including cervical cancer, ovarian cancer, endometrial cancer, and vulvar cancer....

C-reactive protein and 10-year cardiovascular risk in rheumatoid arthritis.

To evaluate the association between C-reactive protein (CRP) and 10-year risk of cardiovascular (CV) events using the Expanded Cardiovascular Risk Prediction Score for Rheumatoid Arthritis (ERS-RA), b... ERS-RA was calculated in 1,251 "Cardiovascular Obesity and Rheumatic Disease Study (CORDIS)" database patients [(age 60.4(9.3) years; 78% female; disease duration, 11.6(8) years; CDAI, 9(9); CRP, 6.8(... The mean (SD) 10-year risk of CV events was 12.9% (10). After adjusting for the use of DMARDs and biologics, CRP concentrations were significantly associated with 10-year risk of CV events (coefficien... In a large cohort of RA patients without previous cardiovascular events, a 20 mg/L increase in CRP concentrations was associated with a 1% increase in 10-year risk of CV events. This suggests that act...

C-reactive protein to lymphocyte count ratio is a promising novel marker in hepatitis C infection: the clear hep-c study.

Chronic hepatitis C (CHC) is one of the most important health problems affecting the significant rate of world population and it may lead to cirrhosis and hepatocellular carcinoma. C-reactive protein ... Patients with CHC infection who visited outpatient and inpatient internal medicine clinics of our institution between January 2021 and December 2021 were enrolled to this retrospective study. CLR of t... Median CLR of CHC and control subjects was 2.61 (5.13%) and 0.31 (0.37%), respectively. CLR of the CHC group was significantly increased compared to the CLR of the controls (p<0.001). There was a sign... Increased CLR in patients with CHC may be an alarming finding of liver fibrosis, as CLR is associated with both CHC and hepatic fibrosis....

Serum C-reactive protein levels are associated with clinical pregnancy rate after

To assess whether low-grade inflammation, measured by serum high-sensitivity C-reactive protein (hsCRP) levels, is associated with... A retrospective study.... University-affiliated IVF center.... In the present study, 875 women of normal weight who underwent their first fresh embryo transfer (ET) cycles for IVF treatment were divided into three groups according to serum concentrations of hsCRP... Serum from women undergoing IVF was collected on days 2-4 of a spontaneous menstrual cycle prior to the commencement of ovarian stimulation.... The IVF outcomes included implantation, biochemical pregnancy, clinical pregnancy, miscarriage and live birth rates.... The women were divided into three groups according to the baseline serum levels of hsCRP as follows: low hsCRP (<1 mg/L; n=517), medium hsCRP (1-3 mg/L; n= 270), high hsCRP (>3 mg/L; n=88). The matern... Among women of normal weight undergoing their first IVF treatment, it was found that low-grade inflammation was associated with reduced clinical pregnancy and live birth rates following fresh ET cycle...

Mortality Risk in Pediatric Sepsis Based on C-reactive Protein and Ferritin Levels.

Interest in using bedside C-reactive protein (CRP) and ferritin levels to identify patients with hyperinflammatory sepsis who might benefit from anti-inflammatory therapies has piqued with the COVID-1... A prospective, observational cohort study.... Children with sepsis and organ failure in nine pediatric intensive care units in the United States.... Two hundred and fifty-five children were enrolled. Five distinct clinical multi-trajectory groups were identified. Plasma CRP (mg/dL), ferritin (ng/mL), and 31 cytokine levels were measured at two tim... Group 1 had normal CRP and ferritin levels ( n = 8; 0% mortality); Group 2 had high CRP levels that became normal, with normal ferritin levels throughout ( n = 80; 5% mortality); Group 3 had high ferr... Bedside CRP and ferritin levels can be used together to distinguish groups of children with sepsis who have different systemic inflammation cytokine responses and mortality risks. These data suggest f...